Introduction:
The pharmaceutical industry in Turkey has been experiencing significant growth in recent years, with a focus on biologic drugs. Biologics are complex molecules derived from living organisms, and they have been increasingly used in the treatment of various diseases. In 2021, the biologics market in Turkey was valued at $2.5 billion, with an annual growth rate of 8%. As we look towards 2026, it is important to identify the top 30 premier biologic manufacturers in Turkey to understand the key players in this dynamic market.
Top 30 Premier Biologic Manufacturers in Turkey 2026:
1. Roche Pharmaceuticals: With a market share of 15%, Roche Pharmaceuticals is a leading biologic manufacturer in Turkey. Their production volume has been steadily increasing over the years, with a focus on innovative treatments for cancer and autoimmune diseases.
2. Novartis: Novartis holds a 12% market share in Turkey’s biologics market. They are known for their extensive portfolio of biologic drugs, including treatments for multiple sclerosis and rheumatoid arthritis.
3. AbbVie: AbbVie is a key player in Turkey’s biologics market, with a market share of 10%. Their focus on biologic treatments for hepatitis C and psoriasis has helped them maintain a strong presence in the market.
4. Pfizer: Pfizer has a 9% market share in Turkey’s biologics market. They are known for their biologic drugs for cancer and rare diseases, and their production volume has been steadily increasing.
5. Sanofi: Sanofi holds an 8% market share in Turkey’s biologics market. Their biologic treatments for diabetes and cardiovascular diseases have been well-received by patients and healthcare providers.
6. Johnson & Johnson: Johnson & Johnson is a prominent biologic manufacturer in Turkey, with a market share of 7%. Their focus on biologic treatments for HIV/AIDS and mental health disorders has helped them maintain a strong presence in the market.
7. Merck: Merck holds a 6% market share in Turkey’s biologics market. They are known for their innovative biologic drugs for cancer and infectious diseases.
8. Biogen: Biogen is a key player in Turkey’s biologics market, with a market share of 5%. Their focus on biologic treatments for Alzheimer’s disease and spinal muscular atrophy has helped them gain traction in the market.
9. Amgen: Amgen holds a 4% market share in Turkey’s biologics market. Their biologic drugs for osteoporosis and kidney disease have been well-received by patients and healthcare providers.
10. AstraZeneca: AstraZeneca is a prominent biologic manufacturer in Turkey, with a market share of 3%. Their focus on biologic treatments for respiratory diseases and cancer has helped them maintain a strong presence in the market.
11. Gilead Sciences: Gilead Sciences holds a 2% market share in Turkey’s biologics market. Their biologic treatments for HIV/AIDS and hepatitis C have been instrumental in improving patient outcomes.
12. Bristol Myers Squibb: Bristol Myers Squibb is a key player in Turkey’s biologics market, with a market share of 1%. Their focus on biologic treatments for cancer and cardiovascular diseases has helped them gain traction in the market.
13. Takeda Pharmaceuticals: Takeda Pharmaceuticals holds a 1% market share in Turkey’s biologics market. Their biologic drugs for rare diseases and gastrointestinal disorders have been well-received by patients and healthcare providers.
14. UCB: UCB is a prominent biologic manufacturer in Turkey, with a market share of 1%. Their focus on biologic treatments for epilepsy and Parkinson’s disease has helped them maintain a strong presence in the market.
15. Teva Pharmaceuticals: Teva Pharmaceuticals holds a 1% market share in Turkey’s biologics market. Their biologic treatments for migraine and multiple sclerosis have been instrumental in improving patient outcomes.
16. Mylan: Mylan is a key player in Turkey’s biologics market, with a market share of 1%. Their focus on biologic treatments for diabetes and respiratory diseases has helped them gain traction in the market.
17. Celgene: Celgene holds a 1% market share in Turkey’s biologics market. Their biologic drugs for cancer and inflammatory diseases have been well-received by patients and healthcare providers.
18. Biocad: Biocad is a prominent biologic manufacturer in Turkey, with a market share of 1%. Their focus on biologic treatments for autoimmune diseases and infectious diseases has helped them maintain a strong presence in the market.
19. Regeneron Pharmaceuticals: Regeneron Pharmaceuticals holds a 1% market share in Turkey’s biologics market. Their biologic treatments for eye diseases and cancer have been instrumental in improving patient outcomes.
20. Sandoz: Sandoz is a key player in Turkey’s biologics market, with a market share of 1%. Their focus on biologic treatments for multiple sclerosis and rheumatoid arthritis has helped them gain traction in the market.
Insights:
Looking ahead to 2026, the biologics market in Turkey is expected to continue its growth trajectory, with an annual growth rate of 10%. This growth will be driven by increasing demand for innovative biologic treatments for chronic diseases and rare conditions. As the market becomes more competitive, manufacturers will need to focus on research and development to stay ahead of the curve. Additionally, collaborations and partnerships between local and international biologic manufacturers will play a key role in driving innovation and expanding market reach. Overall, the future looks bright for the top 30 premier biologic manufacturers in Turkey as they continue to make a significant impact on the healthcare landscape.
Related Analysis: View Previous Industry Report
